Pharmacogenetic study of cholesteryl ester transfer protein gene and simvastatin treatment in hypercholesterolaemic subjects

Expert Opin Pharmacother. 2007 Oct;8(15):2459-63. doi: 10.1517/14656566.8.15.2459.

Abstract

Objective: To examine the effect of the I405V and TaqIB polymorphisms of cholesteryl ester transfer protein (CETP) on the lipid response after simvastatin treatment in 180 hypercholesterolaemic patients.

Methods: Hypercholesterolaemic patients (n = 180) attending the lipid clinic at the Onassis Cardiac Surgery Center were genotyped and their response to simvastatin was evaluated.

Results: Sequence variations in the CETP gene influenced the effect of lipid-lowering treatment. Specifically, the I allele of the I405V polymorphism was associated with a greater reduction in triglyceride (TG; p = 0.04) and a significant increase in high-density lipoprotein cholesterol (HDL-C) levels (p = 0.05) after treatment compared with the V allele.

Conclusions: The authors' findings suggest that CETP I405V polymorphism modifies the effect of simvastatin on TG reduction and HDL-C elevation; the carriers of the I allele responded better to treatment. These findings need to be confirmed in larger studies.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Alleles
  • Cholesterol Ester Transfer Proteins / genetics*
  • Cholesterol, HDL / biosynthesis
  • Cholesterol, HDL / blood
  • Female
  • Humans
  • Hypercholesterolemia / blood
  • Hypercholesterolemia / drug therapy*
  • Hypercholesterolemia / genetics*
  • Male
  • Middle Aged
  • Pharmacogenetics / methods*
  • Polymorphism, Genetic / drug effects
  • Simvastatin / blood
  • Simvastatin / therapeutic use*
  • Triglycerides / antagonists & inhibitors
  • Triglycerides / blood

Substances

  • Cholesterol Ester Transfer Proteins
  • Cholesterol, HDL
  • Triglycerides
  • Simvastatin